MANNKIND CORP Amortization of Debt Issuance Costs
MANNKIND CORP (MNKD) reported Amortization of Debt Issuance Costs of $646.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-02-26
- MANNKIND CORP amortization of debt issuance costs for the quarter ending 2025-12-31 was $425.00K, a 140.11% increase year-over-year.
- MANNKIND CORP amortization of debt issuance costs for the quarter ending 2025-09-30 was $106.00K, a 70.80% decline year-over-year.
- MANNKIND CORP amortization of debt issuance costs for the quarter ending 2025-06-30 was $57.00K, a 84.30% decline year-over-year.
- MANNKIND CORP amortization of debt issuance costs for the quarter ending 2025-03-31 was $57.00K, a 84.30% decline year-over-year.
- MANNKIND CORP amortization of debt issuance costs for fiscal 2025 was $646.00K, a 52.22% decline from fiscal 2024.
- MANNKIND CORP amortization of debt issuance costs for fiscal 2024 was $1.35M, a 7.02% decline from fiscal 2023.
- MANNKIND CORP amortization of debt issuance costs for fiscal 2023 was $1.45M, a 0.07% increase from fiscal 2022.
- MANNKIND CORP amortization of debt issuance costs for fiscal 2022 was $1.45M, a 19.59% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 3 month as first filed | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 6 month as first filed | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $531.00K derived: sum of 2 quarters · filed 2026-02-26 | $588.00K derived: sum of 3 quarters · filed 2026-02-26 | $646.00K 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $106.00K 10-Q · filed 2025-11-05 | $163.00K derived: sum of 2 quarters · filed 2025-11-05 | $221.00K 10-Q · filed 2025-11-05 | $397.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-06-30 | $57.00K 10-Q · filed 2025-08-06 | $115.00K 10-Q · filed 2025-08-06 | $291.00K derived: sum of 3 quarters · filed 2026-02-26 | $654.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-03-31 | $57.00K 10-Q · filed 2025-05-08 | $234.00K derived: sum of 2 quarters · filed 2026-02-26 | $597.00K derived: sum of 3 quarters · filed 2026-02-26 | $960.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $540.00K derived: sum of 2 quarters · filed 2026-02-26 | $903.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.35M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $363.00K 10-Q · filed 2025-11-05 | $726.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.18M 10-Q · filed 2025-11-05 | $1.45M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $363.00K 10-Q · filed 2025-08-06 | $726.00K 10-Q · filed 2025-08-06 | $1.09M derived: sum of 3 quarters · filed 2026-02-26 | $1.45M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $363.00K 10-Q · filed 2025-05-08 | $727.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.09M derived: sum of 3 quarters · filed 2026-02-26 | $1.45M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $727.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.09M derived: sum of 3 quarters · filed 2026-02-26 | $1.45M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $363.00K 10-Q · filed 2024-11-07 | $726.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.09M 10-Q · filed 2024-11-07 | $1.45M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $363.00K 10-Q · filed 2024-08-07 | $727.00K 10-Q · filed 2024-08-07 | $1.09M derived: sum of 3 quarters · filed 2025-02-26 | $1.45M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $363.00K 10-Q · filed 2024-05-08 | $727.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.09M derived: sum of 3 quarters · filed 2025-02-26 | $1.45M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $727.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.09M derived: sum of 3 quarters · filed 2025-02-26 | $1.45M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $363.00K 10-Q · filed 2023-11-07 | $726.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.09M 10-Q · filed 2023-11-07 | $1.45M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $363.00K 10-Q · filed 2023-08-07 | $726.00K 10-Q · filed 2023-08-07 | $1.09M derived: sum of 3 quarters · filed 2024-02-27 | $1.45M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $363.00K 10-Q · filed 2023-05-09 | $726.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.09M derived: sum of 3 quarters · filed 2024-02-27 | $1.45M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $726.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.09M derived: sum of 3 quarters · filed 2024-02-27 | $1.22M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $363.00K 10-Q · filed 2021-11-09 | $726.00K derived: sum of 2 quarters · filed 2021-11-09 | $852.00K 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $363.00K 10-Q · filed 2021-08-11 | $488.00K 10-Q · filed 2021-08-11 | ||||
| 2021-03-31 | $124.00K 10-Q · filed 2021-05-12 | |||||
| 2020-09-30 | $27.00K 10-Q · filed 2021-11-09 | $54.00K derived: sum of 2 quarters · filed 2021-11-09 | $82.00K 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $27.00K 10-Q · filed 2021-08-11 | $55.00K 10-Q · filed 2021-08-11 | ||||
| 2020-03-31 | $27.00K 10-Q · filed 2021-05-12 | |||||
| 2019-09-30 | $34.00K 10-Q · filed 2020-11-04 | $63.00K derived: sum of 2 quarters · filed 2020-11-04 | $84.00K 10-Q · filed 2020-11-04 | $91.00K derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | $29.00K 10-Q · filed 2020-08-05 | $21.00K 10-Q · filed 2019-08-07 | $50.00K 10-Q · filed 2020-08-05 | $35.00K 10-Q · filed 2019-08-07 | $57.00K derived: sum of 3 quarters · filed 2020-08-05 | $71.00K derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $14.00K 10-Q · filed 2019-05-07 | $28.00K derived: sum of 2 quarters · filed 2019-05-07 | $42.00K derived: sum of 3 quarters · filed 2019-05-07 | $52.00K derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $28.00K derived: sum of 2 quarters · filed 2019-02-26 | $38.00K derived: sum of 3 quarters · filed 2019-08-07 | $46.00K 10-K · filed 2019-02-26 | ||
| 2018-09-30 | $14.00K 10-Q · filed 2018-11-01 | $24.00K derived: sum of 2 quarters · filed 2019-08-07 | $32.00K 10-Q · filed 2018-11-01 | $22.00K derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-06-30 | $10.00K 10-Q · filed 2019-08-07 | $17.00K 10-Q · filed 2019-08-07 | $8.00K derived: sum of 3 quarters · filed 2019-08-07 | $15.00K derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-03-31 | $6.00K 10-Q · filed 2019-05-07 | -$2.00K derived: sum of 2 quarters · filed 2019-05-07 | $5.00K derived: sum of 3 quarters · filed 2019-05-07 | $29.00K derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$1.00K derived: sum of 2 quarters · filed 2019-02-26 | $23.00K derived: sum of 3 quarters · filed 2019-02-26 | $31.00K 10-K · filed 2019-02-26 | ||
| 2017-09-30 | $7.00K 10-Q · filed 2018-11-01 | $31.00K derived: sum of 2 quarters · filed 2018-11-01 | $39.00K 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | $24.00K 10-Q · filed 2018-08-02 | $32.00K 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | $9.00K 10-Q · filed 2018-05-09 | |||||
| 2016-12-31 | $35.00K 10-K · filed 2019-02-26 | |||||
| 2015-12-31 | $35.00K 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |